


What is NKG2D?

Natural Killer Group 2D (NKG2D) is an activating receptor exploited by natural killer cells to protect against viral infections. The NKG2D receptor binds to eight stress ligands that are broadly expressed across most solid tumors and hematological malignancies. Putting the NKG2D CAR onto a T cell exploits this multi-tumor specificity while avoiding the many mechanisms used by tumors that blunt NK cell killing.

NKG2D-based CAR



- Engineering the NKG2D receptor with the CD3ζ domain produces a CAR which allows the T cell to target any of the eight stress ligands
- Our clinical data to date has shown no evidence of 'on-target, off-tissue' toxicity, exemplifying the strong safety profile of the NKG2D CAR T

Market Potential for NKG2D receptor-based therapies

Total market potential is **870,530 patients/year**

